Polycarbonate Market Revenue, SWOT, PEST Analysis, Growth Factors, 2030 Read More: https://www.emergenresearch.com/industry-report/polycarbonate-market The global polycarbonate market size reached USD 21.50 Billion in 2021 and is expected to register a revenue CAGR of 5.6% during the forecast period, according to latest analysis by Emergen Research. Polycarbonate market revenue growth is driven by factors such as rising demand for spike temperature resistance, flexibility & toughness in thin sections, growing demand from electric vehicles and the medical industry, and the development of bio-based polymers.

Interactive Whiteboard Market opportunity Analysis and Industry report of forecaste period to 2030 Read More: https://www.emergenresearch.com/industry-report/interactive-whiteboard-market The global Interactive Whiteboard (IWB) market size was USD 1,816.0 Million in 2021 and is expected to register a revenue CAGR of 7.42% during the forecast period, according to the latest analysis by Emergen Research. Rising demand for digital solutions due to COVID-19 and increasing adoption of advanced learning methods, such as virtual learning, are major factors projected to drive market revenue growth between 2021 and 2030.

Fire Alarm Market Size, Share Analysis, Key Companies, and Forecast To 2030 Read More: https://www.emergenresearch.com/industry-report/fire-alarm-market The global fire alarm market size was USD 30.20 Billion in 2021 and register a revenue CAGR of 7.2% over the forecast period, according to the latest analysis by Emergen Research. Strong government regulations to adopt fire detection and alarm systems in infrastructure projects and rapid development of sensor technology are key factors driving global fire alarm market revenue growth.

US Connected Toys Market Size, Top Trends - Industry Revenue, Forecast to 2022-2030 Read More: https://www.emergenresearch.com/industry-report/connected-toys-market The global connected toys market size is expected to reach USD 36.63 Billion at a steady revenue CAGR of 20.9% in 2030, according to the latest analysis by Emergen Research. Shift toward two working parents giving rise to the monitoring and tracking of toy devices can be attributed to the steady market revenue growth of connected toys. In OECD countries in 2019, the average percentage of working mothers was 70.9%. 45.6% of two-partner households have both partners employed full-time.

The bioavailability enhancement services market is projected to grow at an annualized rate of 11.12% during the period 2021-2035, claims Roots Analysis The bioavailability enhancement process is known to be fraught with several challenges, including its time and cost intensive nature; given the expertise available with service providers to improve pharmacokinetic properties of novel molecules, developers are actively outsourcing their requirements Roots Analysis has announced the addition of “Bioavailability Enhancement Technologies and Services Market (2nd Edition), 2022-2035” report to its list of offerings Considering the existing drug solubility and biocompatibility-related concerns and their impact on drug safety and patient compliance, the demand for bioavailability enhancement solutions has gained significant traction from the medical community. Drug developers have demonstrated a preference to continue relying on bioavailability enhancement service and technology providers, in order to optimize drug development cost and research timelines. Furthermore, driven by the large number of BCS class II and IV therapies in the current pipeline and growing demand for effective therapeutics, the bioavailability enhancement services market is expected to grow at a steady pace in the foreseen future. Key Market Insights ~115 players currently claim to be engaged in providing bioavailability enhancement services The bioavailability enhancement services market landscape is primarily characterized by the presence of small, mid-sized and large firms, which collectively constitute over 75% of the total share. Further, 45% of the service providers are based in North America, followed those having headquarters in Europe and Asia. More than 75 bioavailability enhancement technologies are presently available in the market Most (55%) of these technologies support solubility enhancement, followed by those providing support for sustained release drug delivery (46%). Additionally, nearly 70% of the technologies provide bioavailability enhancement services for solids, followed by liquids and fine particles / powders. Partnership activity in this field has increased at a CAGR of nearly 35%, between 2013 and 2022 Mergers and acquisitions (~40%) emerged as the most common type of partnership models adopted by stakeholders engaged in this industry. Nearly 55% of the total deals were established post-2018, with the maximum activity being reported in 2021. >9,600 patents related to bioavailability enhancement have been filed / granted, during 2003-2022 Majority (~80%) of the patents were filed as applications, followed by granted patents (20%). It is important to highlight that, nearly 1,200 patents were filed / granted in the year 2021. Further, 36% of the total patents were filed in North America, indicating the extensive R&D activity in this region. 4,700+ clinical trials evaluating bioavailability of drug candidates have been registered worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 24%, during the period 2010-2022. Of the total, more than 85% of the studies have already been completed, followed by active trials that are actively recruiting patients (~10%). Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by stakeholders The framework highlights the implementation of several advanced as well as traditional bioavailability enhancement approaches and technologies at different stages of the drug development pathway. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating such technologies, based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. Shifting focus of drug developers towards development of lipophilic drug compounds is anticipated to drive the demand for bioavailability enhancement technologies and services in the next 13 years The outsourced commercial demand for bioavailability enhancement is projected to increase at a CAGR of ~10 %. Further, the current clinical demand for solid dosage form captures around 30% of the total demand. North America and Europe are anticipated to capture more than 65% of the market share, by 2035 Owing to the high prevalence of diseases, increasing investments in formulation development research, and growing initiatives for drug discovery and personalized medicine in Asia, the bioavailability enhancement services market in Asia is likely to grow at a relatively faster pace (13.54%) in the long term. Further, in 2035, bioavailability enhancement services for new chemical entities are expected to dominate the market, capturing around 85% of the market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/198/request-sample.html Key Questions Answered  Who are the key players engaged in the bioavailability enhancement technologies and services market?  Which are the key geographies where bioavailability enhancement technology and service providers are located?  What are the recent developments and expected trends in the bioavailability enhancement industry?  Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?  What is the evolving trend of publications focused on bioavailability enhancement technologies?  Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?  What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement services market?  How is the current and future opportunity likely to be distributed across key market segment? The financial opportunity within the bioavailability enhancement services market has been analyzed across the following segments:  Drug Class  New Drug Approvals  Generics  BCS Classification  BCS II Drugs  BCS IV Drugs  Bioavailability Enhancement Approach  Solid Dispersion  Size Reduction  Lipid-based  Dosage Form  Liquids  Solids  Semi-Solids  Fine Particles / Powders  Key Geographies  North America  Europe  Asia  Latin America  Middle East and North Africa (MENA)  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), recent developments (including partnerships and collaborations) and an informed future outlook.  Adare Pharma Solutions  Ascendia Pharmaceuticals  Catalent  Lonza  Lubrizol Life Science Health  Pace Life Sciences  Quotient Sciences  WuXi STA (a subsidiary of WuXi AppTec) For additional details, please visit https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The global monkeypox therapeutics and vaccines market and global monkeypox diagnostic kits market is likely to grow at a healthy pace in the foreseen future, claims Roots Analysis Post the global outbreak of the monkeypox disease in early 2022, there has been a surge in interest towards research for effective and safe vaccines / therapeutics intended for the management / treatment of disease symptoms Roots Analysis has announced the addition of “Monkeypox Market: Focus on Therapeutics, Vaccines and Diagnostic Kits, 2023-2035” report to its list of offerings. Given the increase in research and development activity in this domain and the substantial financial assistance provided by public funding institutes, the monkeypox therapeutics / vaccines and diagnostic kits market is projected to grow at a steady pace in the near future. The recent rise in the incidence of the monkeypox disease, also known as Mpox, has compelled both industry players and regional government authorities to undertake active initiatives in order to control the spread of the disease To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/monkeypox-treatment-market/request-sample.html Key Market Insights 25+ monkeypox therapeutics and vaccines are currently approved / under development More than 20% of the aforementioned candidates are approved or have been granted expanded access for the treatment / prevention of monkeypox. Further, 70% of the total candidates are in preclinical stages of development. Over 120 developers claim to provide diagnostic kits for monkeypox virus detection Interestingly, nearly 65% of the diagnostic kit providers are based in Asia-Pacific and rest of the world. Notably, around 50% of the total players engaged in this space are mid-sized firms. Partnership activity within this domain has grown at a CAGR of ~150%, between 2018 and 2022 More than 85% of the partnerships were inked in the year 2022, indicating the recent surge in interest of industry stakeholders in this domain. More than 250 grants have been awarded for research related to monkeypox therapeutics, vaccines and diagnostic solutions Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, microbiology / immunology / virology departments emerged as the key research departments, having received over 35% of the total grants. Over 230 articles related to monkeypox therapeutics, vaccines and diagnostic kits have been published between 2018 and 2022 35% of the articles published in this domain were research papers, followed by review papers (12%). North America and Europe are anticipated to capture close to 95% share of the monkeypox therapeutics and vaccines market, by 2035 The monkeypox therapeutics / vaccines market’s evolution is likely to be driven by the rising need for novel drug candidates. In terms of type of product, vaccines are expected to occupy a larger share (99%) of the overall monkeypox therapeutics and vaccines market in 2035. PCR Kits are anticipated to capture more than 70% share of the monkeypox diagnostic kits market, by 2035 In the long term, hospitals and clinics are likely to contribute to a majority share (~50%) of revenues as end users. The research also includes detailed profiles of key players (listed below) engaged in the monkeypox therapeutics / vaccines and diagnostic kits markets; each profile features a brief overview of the company, details related to its product portfolio (therapeutics / vaccines or diagnostic kits), recent developments and an informed future outlook.  Bavarian Nordic  Emergent BioSolutions  ACON Laboratories  altona Diagnostics  DNA Software  Elabscience  Goldsite Diagnostics  Hangzhou Testsea Biotechnology  Jiangsu Bioperfectus Technologies  Lansion Biotechnology For additional details, please visit https://www.rootsanalysis.com/reports/monkeypox-treatment-market.html You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The Satta King is a deadly bowling league paddle. That is what it was designed for. It is a full sized paddle that can do some serious damage to any novice players who don't have the slightest idea on how to handle or improve their skills on bowling. That is exactly the reason why many people love to https://sattakingm.in/ #Satta, #Satta_King, #SattaKing, #AJMERKING, #sattakingfast, #playbazaar, #blacksattaking, #blacksatta , # shalimargame, # sattaking, #delhisattabajar, #दिल्लीदिसावर

LIPOSOME – A TRENDING NOVEL DRUG DELIVERY SYSTEM In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules, liposomes are extensively used as efficient delivery systems for antigens or drugs. They can protect a drug from being detected by the body’s immune system by imitating biological membranes and providing the drug more time to reach its target destination. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market/request-sample.html Liposomes offer great therapeutic efficacy and safety. They have several applications in the biomedical field such as delivering drug to the desired site while minimizing drug exposure to normal tissues, increased delivery of potential medications to the cytosol, stabilizing therapeutic compounds, and removing barriers to cellular and tissue absorption. In addition to the applications, liposomes are gaining popularity across various other fields, including drug delivery, agriculture, cosmetics, and food industry. Due to multiple advantages across diverse application areas, including enhanced biocompatibility, high biodegradability, low toxicity, weak immunogenicity, increased drug solubility, controlled distribution, ability to make surface modifications for targeted, extended, and sustained release, liposomes have been recognized as the most effective delivery system. Currently, there are several liposomal formulations clinically approved for the treatment of various diseases, including cancer, fungal and viral infections, and many are currently in advanced stages of clinical studies. Over the years, several companies involved in the development of liposomes have made significant efforts in conducting clinical trials for evaluating the efficacy of liposome-based therapeutics, for the treatment of various oncological disorders. Owing to various advantages offered by liposomes, advanced liposome technology is being developed to fully substructure the therapeutic applications of liposomes and extensive research is being conducted to develop methods for liposomal formulation with high level of purity and sensitivity. Further, it is extremely desirable to develop novel manufacturing methods that allow for simple encapsulation of both hydrophobic and hydrophilic molecules without the need of organic solvents, specialized equipment, or complex infrastructures. Additionally, given that liposomes have demonstrated some clinical promise as drug delivery systems, future efforts should focus on enhancing the commercial availability and accessibility of liposome products across the globe, particularly in low- and middle-income countries. applications of liposomes in drug delivery (24%), and protein and peptide delivery (9%), which is indicative of the extensive research activities and clinical trials being conducted to evaluate the therapeutic potential of liposomes. Despite several advancements, there are various challenges in development of liposomes, for which stakeholders are leveraging the expertise of various contract service providers offering development and manufacturing services. These service providers are actively upgrading their capabilities and infrastructure to accommodate the demand for these vesicles. Driven by the growing research efforts, development of advanced methods for preparation and characterization of liposomes, and efforts of various stakeholders, this segment of industry is likely to witness noteworthy growth in the foreseen future. For additional details, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The exosome therapeutics market is anticipated to grow at a commendable pace by 2040, claims Roots Analysis Owing to their potential in effective intracellular shuttling, therapeutic molecular delivery and treatment of multiple disorders, exosomes have garnered significant attention of researchers and industry stakeholders in the past few years Roots Analysis is pleased to announce the publication of its recent study, titled, “Exosome Therapeutics Market, 2022-2040.” The report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/exosome-therapeutics-market/request-sample.html The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of drug developers engaged in the development of exosome (membrane bound extracellular vesicles) therapeutics.  Detailed profiles of key players involved in the development of exosome therapeutics (shortlisted on the basis of the number of pipeline products).  Detailed drug profiles of key therapeutics in the highest phase of development.  A detailed analysis of more than 50 completed, ongoing and planned clinical studies of exosome therapeutics.  An in-depth analysis of more than 500 academic grants that have been awarded to research institutes engaged in exosome therapeutics-related projects.  A detailed analysis of the global events attended by the exosome therapy developers.  An analysis of the partnerships that have been established in this domain, in the recent past.  An in-depth analysis of various investments made since 2017.  An analysis of start-ups / small companies engaged in the development of exosome therapeutics.  A case study highlighting the companies engaged in offering exosome development and manufacturing services.  An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Therapeutic  Allogeneic Therapy  AutologousTherapy  Target Indication(s)  Degenerative Meniscal Injury  Dystrophic Epidermolysis Bullosa  Fistula Perianal  Retinitis Pigmentosa  Therapeutic Area  Dermatological Disorders  Muscoskeletal Disorders  Ophthalmic Diseases  Rectal Disorders  Route of Administration  Fistula Tract  Intra-articular  Intra-ocular  Geography  North America  Europe  Asia-Pacific and Rest of the World Key companies covered in the report  Codiak BioSciences  Coya Therapeutics  Curexsys  EV Therapeutics  Evox Therapeutics  SHIFTBIO  AEGLE Therapeutics  AVEM Healthcare  Cellular Biomedicine Group  OBCTCD24  ReNeuron  Stem Cell Medicine For more information, please click on the following link: https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The spatial omics solutions market is anticipated to grow at a CAGR of 11.9%, till 2035, claims Roots Analysis Recent advancements in multiplexed profiling and tissue imaging methods have enabled the assessment of spatial heterogeneity in intact tissues; as a result, adoption of spatial omics solutions offering benefits over traditional methods, is increasing Roots Analysis has announced the addition of “Spatial Genomics, Transcriptomics and Proteomics Solutions Market, 2022-2035” report to its list of offerings. Currently used histological methods measure limited number of biomarkers at a time and the fluorescent tags introduced interfere with the natural function of genes and proteins. Stakeholders are on the lookout for platforms that can simultaneously capture the arrangement of multiple biomolecules with single-cell or subcellular resolution, while preserving the tissue integrity. The up-and-coming field of spatial biology addresses this unmet need, while bridging the gap between high plex, high throughput, and high resolution. Key Market Insights Presently, 45 industry and non-industry players claim to offer spatial genomics, spatial transcriptomics and spatial proteomics solutions Majority (72%) of the solution providers are based in North America, followed by those headquartered in Europe (22%). A large proportion (50%) of these companies are large players, followed by small (30%) and mid-sized firms (20%). More than 70 solutions are available / being developed for spatial profiling of biomolecules Majority (51%) of the solutions are used for analyzing RNA transcripts, followed by 26% and 15% of the solutions that can analyze protein signatures and DNA molecules, respectively. Partnership activity in this field has increased at a CAGR of over 70%, between 2016 and 2020 The highest number of partnership agreements (16) were signed in 2021. Majority of the partnerships (31%) were signed for technology / platform integration; followed by deals inked for commercialization of spatial omics solutions. Grants worth over USD 20 million have been awarded to support research on spatial omics solutions, since 2018 Till June 2022, over 15 grants have been awarded for the research projects related to spatial phenotyping and profiling of biomolecules targeting various oncological and non-oncological disorders. Around 38% of the total number of grants were provided by the National Institutes of Health (NIH). More than 530 patents have been filed / granted for spatial omics solutions, since 2003 Close to 70% of the patent applications have been filed by various industry and non-industry players in this domain, post 2018. It is worth noting that, around 49% of the patents were filed / granted in the US, followed by World Intellectual Property Organization (35%). North America is anticipated to capture larger share of the spatial omics solutions market by 2035 North America has currently captured half of the overall market share and is estimated to be worth USD 9.61 billion by 2035, growing at a CAGR of 11.5%. This is closely followed by Europe, which is estimated to be worth USD 6.65 billion in 2035, growing at a double digit CAGR. Instruments are anticipated to capture larger share of the market by 2035 Our estimates suggest that the overall market is likely to be driven by the revenues generated through the sales of spatial-omics instruments in the foreseen future due to their high cost. Further, the share of consumables and software is expected to grow at a relatively faster pace (12.7%), during the given period. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/spatial-genomics-market/request-sample.html Key Questions Answered  Which are the key geographies where spatial omics solutions providers are located?  Which analytical techniques are leveraged by players offering spatial omics solutions?  Who are the leading players involved in the development of spatial omics solutions?  What are the key research areas where spatial analytical solutions can be employed? Which partnership models are commonly adopted by stakeholders offering spatial profiling solutions?  What is the evolving trend of publications focused on spatial analysis-based technologies?  Who are the key investors in spatial omics solutions market? The financial opportunity within the spatial genomics, spatial transcriptomics and spatial proteomics market has been analyzed across the following segments:  Type of Solution  Instruments  Consumables  Services  Sample Type  DNA  RNA  Protein  Research Area  Oncological Disorders  Immunological Disorders  Neurological Disorders  Infectious Diseases  Others  End User  Pharmaceutical and Biotechnology Companies  Academic and Research Institutes  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The report includes detailed profiles of key players (listed below), each featuring an overview of the company, its financial information (if available), a description of the spatial omics solutions offered, details of recent developments along with an informed future outlook.  10x Genomics  Akoya Biosciences  Bruker  Canopy Biosciences  NanoString Technologies  Vizgen  Lunaphore Technologies  Molecular Machines & Industries (MMI)  Resolve Biosciences The opinions and insights presented in the report were influenced by discussions held with several stakeholders engaged in this domain. The report includes detailed transcripts of discussions (in reverse chronological order) held with the following experts:  Sean Bendall (Co-founder, Ionpath)  Priyam Shah (Senior Director, Akoya Biosciences)  Brad Nelson (Senior Vice President of Marketing, Ionpath) For additional details, please visit https://www.rootsanalysis.com/reports/spatial-genomics-market.html You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com